Skip to main content
Adalyne, a child with SMA, in wheelchair, eagerly petting a dog as her mother, Patti, holds the dog next to her

Children treated after showing SMA symptoms (symptomatic)

Adalyne has 2 copies of SMN2 gene
Treated at ~2½ months old

After receiving treatment with ZOLGENSMA, 
Adalyne received another SMA treatment.

ZOLGENSMA® (onasemnogene abeparvovec-xioi) was studied in children who were showing symptoms (symptomatic) of spinal muscular atrophy (SMA) before treatment. The key trial looked at safety and efficacy and was called STR1VE. ZOLGENSMA was also studied in symptomatic children in a trial called START, which studied safety and dosing.

See the safety profile of ZOLGENSMA

Get your child started with ZOLGENSMA